4Savage P. Clinical observations on chemotherapy curable malig nancies; unique genetic events, frozen development and endur ing apoptotic potential[J]. BMC Cancer, 2015, 15(1) .-11.
5Chen L, Liu T, Zhou J, et al. Citrate synthase expression af fects tumor phenotype and drug resistance in human ovariancar einoma[-J]. PLoSOne, 2014, 9(12);e115708.
6Turan G, Usta CS, Usta A, et al. The expression of HER-2/ neu (c-erbB2), survivin and cycline D1 in serous ovarian neo- plasms: their correlation with clinicopathological variables[J]. J Mol Histol, 2014, 45(6):679-687.
7G sowska-Bodnar A, Bodnar L, D bek A, et al. Survivin expression as a prognostic factor in patients with epithelial o- varian cancer or primary peritoneal cancer treated with neoadju- rant chemotherapy[J]. Int J Gynecol Cancer, 2014, 24(4): 687-696.
8Zou L, Yi T, Song X, et all. Efficient inhibition of intraperito- neal human ovarian cancer growth by short hairpin RNA tar- getingCD44[J]. Neoplasma, 2014, 61(3) :274 282.
9Du YR, Chen Y, Gao Y, et all. Effects and mechanisms of an- ti-CD44 monoclonal antibody A3D8 on proliferation and apopto- sis of sphere-forming cells with stemness from human ovarian cancer[J]. Int J GynecolCancer, 2013, 23(8):1367-1375.
10Xie X, Long L, Wang H, ET all. The specifical inhibition of the expression of integrin alpha5/betal probably enhances the treatment effects and improves the prognosis of epithelial ovari- an cancer [J]. Med Hypotheses, 2015, 84(1);68-71.
